Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVU...
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 0.0% | ||
| P/E Ratio | -109.7x | ||
| Revenue | 2.248 B | ||
| Net Income to Company | -278.2 M |
| ALNY | Peers | Sector | |
|---|---|---|---|
Market Cap | 30.157 B | 308.4 M | 58.13 M |
Price % of 52 Week High | 77.4% | 29.5% | 56.8% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | -1.2% | -33.2% | -0.8% |
1 Year Price Total Return | 49.3% | -60.8% | -19.1% |
Beta (5 Year) | 0.30 | 1.58 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 1,037 | 1,828 | 2,248 | 440 | 593 |
| Operating Income | (785) | (282) | (177) | (116) | (105) |
| Net Profit | (1,131) | (440) | (278) | (138) | (84) |
| Diluted EPS | -9.30 | -3.52 | -2.18 | -1.10 | -0.65 |
| EBITDA | (741) | (228) | (120) | (103) | (91) |
| Balance Sheet | |||||
| Cash & ST Invest. | 2,192 | 2,439 | 2,695 | 2,439 | 2,695 |
| Current Assets | 2,692 | 2,983 | 3,295 | 2,983 | 3,295 |
| Total Assets | 3,546 | 3,830 | 4,240 | 3,830 | 4,240 |
| Current Liabilities | 768 | 968 | 1,186 | 968 | 1,186 |
| Total Liabilities | 3,705 | 4,051 | 4,173 | 4,051 | 4,173 |
| Total Equity | (158) | (221) | 67 | (221) | 67 |
| Total Debt | 2,613 | 2,683 | 2,743 | 2,683 | 2,743 |
| Cash Flow Statement | |||||
| Cash Flow Operations | (541) | 104 | (8.31) | (30) | (95) |
| Cash From Investing | 169 | (336) | (117) | (241) | (53) |
| Cash From Financing | 426 | 172 | 294 | 39 | 31 |
| Free Cash Flow | (613) | 42 | (43) | (45) | (104) |